Steve Schonfeld’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $621K | Sell |
12,964
-89,076
| -87% | -$3.83M | ﹤0.01% | 1720 |
|
|
2026
Q1 | $3.75M | Buy |
+102,040
| New | +$4.83M | 0.03% | 584 |
|
|
2025
Q4 | – | Sell |
-557,519
| Closed | -$28.5M | – | 2422 |
|
|
2025
Q3 | $30.9M | Buy |
+557,519
| New | +$32.6M | 0.18% | 98 |
|
|
2025
Q2 | – | Sell |
-156,635
| Closed | -$10.9M | – | 2389 |
|
|
2025
Q1 | $10.9M | Buy |
+156,635
| New | +$12.9M | 0.07% | 292 |
|
|
2024
Q4 | – | Sell |
-70,925
| Closed | -$8.45M | – | 2275 |
|
|
2024
Q3 | $8.45M | Buy |
+70,925
| New | +$9.46M | 0.06% | 348 |
|
|
2024
Q2 | – | Sell |
-3,200
| Closed | -$411K | – | 2448 |
|
|
2024
Q1 | $411K | Buy |
+3,200
| New | +$381K | ﹤0.01% | 1543 |
|
|
2023
Q3 | – | Sell |
-200
| Closed | -$16.2K | – | 2129 |
|
|
2023
Q2 | $16.2K | Sell |
200
-2,000
| -91% | -$163K | ﹤0.01% | 1901 |
|
|
2023
Q1 | $175K | Buy |
+2,200
| New | +$156K | ﹤0.01% | 1574 |
|
|
2022
Q4 | – | Sell |
-7,600
| Closed | -$379K | – | 2879 |
|
|
2022
Q3 | $379K | Sell |
7,600
-101,060
| -93% | -$5.41M | ﹤0.01% | 1940 |
|
|
2022
Q2 | $6.05M | Sell |
108,660
-110,502
| -50% | -$6.13M | 0.06% | 417 |
|
|
2022
Q1 | $12.2M | Buy |
+219,162
| New | +$11.2M | 0.11% | 227 |
|
|
2021
Q4 | – | Sell |
-103,884
| Closed | -$4.99M | – | 2411 |
|
|
2021
Q3 | $4.99M | Buy |
103,884
+50,484
| +95% | +$2.44M | 0.05% | 439 |
|
|
2021
Q2 | $2.24M | Sell |
53,400
-64,948
| -55% | -$2.52M | 0.02% | 672 |
|
|
2021
Q1 | $3.99M | Sell |
118,348
-1,052
| -0.9% | -$37.5K | 0.05% | 491 |
|
|
2020
Q4 | $4.17M | Buy |
+119,400
| New | +$4.13M | 0.06% | 437 |
|
|
2020
Q1 | – | Sell |
-10,366
| Closed | -$300K | – | 1399 |
|
|
2019
Q4 | $300K | Buy |
+10,366
| New | +$287K | 0.01% | 968 |
|
|
2018
Q4 | – | Sell |
-62,520
| Closed | -$1.47M | – | 1191 |
|
|
2018
Q3 | $1.47M | Buy |
62,520
+396
| +0.6% | +$9.66K | 0.07% | 352 |
|
|
2018
Q2 | $1.43M | Buy |
+62,124
| New | +$1.48M | 0.08% | 332 |
|
|
2017
Q4 | – | Sell |
-53,086
| Closed | -$1.28M | – | 837 |
|
|
2017
Q3 | $1.28M | Buy |
+53,086
| New | +$1.2M | 0.12% | 226 |
|
|
2017
Q1 | – | Sell |
-39,756
| Closed | -$713K | – | 694 |
|
|
2016
Q4 | $713K | Sell |
39,756
-76,566
| -66% | -$1.39M | 0.09% | 275 |
|
|
2016
Q3 | $2.42M | Buy |
+116,322
| New | +$2.88M | 0.41% | 61 |
|
|
2016
Q2 | – | Sell |
-12,760
| Closed | -$346K | – | 499 |
|
|
2016
Q1 | $346K | Buy |
+12,760
| New | +$342K | 0.14% | 197 |
|
Other funds holding NVO
F
Steve Schonfeld's NVO Position: Q2 2026 in Review
Steve Schonfeld reduced its Novo Nordisk (NVO) stake by 87% in Q2 2026, selling an estimated $3.83M and leaving 12,964 shares worth $621K. The position accounts for ﹤0.01% of the portfolio, ranked #1720.
Steve Schonfeld first reported a position in NVO in Q1 2016 and has held it in 22 quarters since. The position peaked at $30.9M in Q3 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Steve Schonfeld held 12,964 shares of Novo Nordisk worth $621K as of Q2 2026.
- Steve Schonfeld sold 89,076 Novo Nordisk shares in Q2 2026, an estimated $3.83M.
- Novo Nordisk made up ﹤0.01% of Steve Schonfeld's portfolio in Q2 2026, its #1720 holding.
- Steve Schonfeld first reported a position in Novo Nordisk in Q1 2016 and has held it in 22 quarters since.
- Steve Schonfeld's Novo Nordisk position peaked at $30.9M in Q3 2025.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.